The calcium gluconate market has seen considerable growth due to a variety of factors.
• The calcium gluconate market has grown rapidly, with the market expected to rise from $110.12 billion in 2024 to $119.38 billion in 2025 at a CAGR of 8.4%.
Growth is attributed to economic growth, industrialization, increased use in functional foods, rising demand for pharmaceuticals and dietary supplements, and regulatory support for food additives.
The calcium gluconate market is expected to maintain its strong growth trajectory in upcoming years.
• The calcium gluconate market is projected to grow to $162.69 billion by 2029, with a CAGR of 8.0%.
This growth is attributed to an aging population, increased health consciousness, the expansion of the food and beverage sector, digital marketing, a shift towards natural products, emerging markets, and urbanization. Major trends include research focused on sustainable sourcing, the integration of calcium gluconate in medical treatments, custom formulations, and advancements in manufacturing technologies.
Rising healthcare expenditure is expected to boost the calcium gluconate market. With healthcare spending growing due to aging populations and more chronic disease cases, the demand for calcium gluconate—used to treat hypocalcemia and related conditions—is on the rise. In the UK, health spending is projected to reach £192 billion in 2024/25, signaling increased demand for related treatments.
The calcium gluconate market covered in this report is segmented –
1) By Form: Liquid, Tablet, Powder, Gel
2) By Grade: Pharmaceutical Grade, Food Grade
3) By Application: Food And Beverage Manufacturers, Pharmaceutical, Nutraceutical, Cosmetic And Personal Care, Other Applications
4) By End Use: Emulsifier, Bulking Agent, Thickening Agent
Subsegments:
1) By Liquid: Injectable Solution, Oral Liquid, IV Infusion
2) By Tablet: Standard Tablets, Effervescent Tablets
3) By Powder: Oral Powder, Injectable Powder
4) By Gel: Topical Gel, Transdermal Gel
Companies in the calcium gluconate market are focusing on drug development to treat calcium deficiencies and related conditions. For instance, in September 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, received FDA approval for its calcium gluconate in sodium chloride injection, designed for treating acute symptomatic hypocalcemia in both pediatric and adult patients. The product, available in 1000 mg/50 mL and 2000 mg/100 mL doses, was approved with the Competitive Generic Therapy (CGT) designation and comes with a 180-day exclusivity period.
Major companies operating in the calcium gluconate market are:
• Merck & Co. Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Novartis AG
• Eli Lilly and Company
• Solvay
• Viatris Inc.
• Baxter International Inc.
• Fresenius Kabi USA
• Hikma Pharmaceuticals Inc.
• Amneal Pharmaceuticals Private Limited
• Amphastar Pharmaceuticals
• Jost Chemical Co.
• American Regent Inc.
• Coyne Chemical
• Anhui Xingzhou Medicine Food Co. Ltd.
• Westco Chemicals Inc.
• Noah chemicals
• ND Biotech Pvt Ltd
• Global Calcium Private Limited
• Foodchem
• Pharma Cure Laboratories
• Nivagen Pharmaceuticals Inc.
• Tianyi Food Additives Co. Ltd
Europe was the largest region in the calcium gluconate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcium gluconate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.